A major randomized trial challenges the assumed benefit of tumor debulking in advanced colorectal cancer, showing no survival gain despite increased risks and raising questions about its role in routine care.
Study: Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer. Image credit: 3dMediSphere/Shutterstock.com
Tumor debulking combined with standard first-line palliative chemotherapy does not improve survival outcomes in patients with multiorgan metastatic colorectal cancer (mCRC) over chemotherapy alone, according to a study published in JAMA.
Can debulking extend benefits to widespread metastases?
Colorectal cancer (CRC) remains one of the most commonly diagnosed malignancies worldwide and a leading cause of cancer-related mortality. Despite advances in screening and treatment, up to half of patients ultimately develop metastatic disease, which is associated with markedly poorer outcomes.
In selected patients with limited metastatic spread, however, aggressive local treatments such as surgical resection and thermal ablation have transformed prognosis. These approaches can achieve five-year survival rates of 35 % to 65 %, while parallel advances in systemic therapies have extended median overall survival beyond 30 months.
Building on these successes, there has been growing interest in extending local treatment strategies to patients with more extensive metastatic colorectal cancer (mCRC), including the use of tumor debulking alongside systemic chemotherapy. However, whether such approaches translate into meaningful survival benefits in patients with multiorgan metastatic disease remains uncertain, with limited evidence from prospective randomized trials.
ORCHESTRA trial tests debulking in advanced mCRC
The researchers conducted the ORCHESTRA trial, a randomized, open-label, phase 3 clinical trial involving 382 patients with mCRC. Most were treated at hospitals in the Netherlands. All patients had tumors that could be debulked by at least 80 % as assessed prior to randomization, before beginning first-line palliative chemotherapy. The study's aim was to determine whether debulking would increase overall survival by at least six months.
Before randomization, all patients received initial chemotherapy with standard CRC drugs. Only participants who responded to the chemotherapy or had stable disease continued in the study. The participants were then randomized to receive either chemotherapy alone or chemotherapy plus debulking.
The aim of the study was to assess whether the addition of debulking could increase overall survival by at least six months. In addition, the researchers assessed survival in subgroups stratified by various tumor markers, including CEA and BRAF V600E, which were evaluated for their prognostic association with survival outcomes.
No survival benefit despite added tumor debulking
Participants in both groups were predominantly male. Overall, the study found no significant difference in either overall survival or progression-free survival between patients receiving chemotherapy alone and those receiving chemotherapy plus tumor debulking. However, the addition of debulking was associated with a higher burden of toxicity, with a 14.62 percentage-point increase in serious adverse events (53 % vs 39 %). These findings do not support the assumption that local treatment can reduce chemotherapy-related toxicity by delaying or interrupting systemic therapy. Notably, quality-of-life outcomes were similar across both treatment groups.
Treatment exposure also differed between the groups. Fewer patients in the debulking arm completed at least six months of chemotherapy compared with those receiving chemotherapy alone. The authors suggest this may reflect factors such as disease progression during local therapy or reduced ability or willingness to resume systemic treatment following debulking procedures.
The study population represents a specific subgroup of patients with multiorgan metastatic CRC, and the results may not be directly applicable to those with more limited metastatic disease. Even so, subgroup analyses of patients with liver- or lung-limited metastases did not demonstrate an overall survival benefit with debulking. However, the authors emphasize that the trial was not designed or powered to definitively assess outcomes in these more restricted subgroups.
Consistent with the overall findings, progression-free survival was similar across treatment groups, as observed in prior studies. While this suggests that reducing tumor burden through debulking may not delay disease progression, the authors caution against overinterpretation, particularly in patients with less extensive disease, where the trial lacked statistical power.
One exploratory subgroup analysis suggested an overall survival benefit among patients with stable disease at randomization. However, this signal was difficult to interpret because it was not accompanied by a corresponding improvement in progression-free survival, thereby limiting its clinical significance.
Study limitations
The study compared two subgroups, but its conclusions may be weakened due to a ten-year recruitment period, causing outdated metrics, and modern chemotherapy regimens were not used, potentially reducing success rates
Nevertheless, both groups experienced these limitations, which are therefore unlikely to change the overall findings, and the authors note that survival outcomes were broadly consistent with more recent first-line chemotherapy trials, suggesting these factors are unlikely to meaningfully alter the study conclusions.
Debulking adds risk without extending survival outcomes
This study shows that tumor debulking plus systemic chemotherapy does not improve overall survival in mCRC patients compared to chemotherapy alone, and may increase the risk of serious adverse effects. Based on these findings, such an approach is not supported for routine use.
The authors comment, “These results highlight the importance of prospective randomized clinical trials when considering the role of local therapies in the treatment of patients with mCRC.”
Download your PDF copy by clicking here.
International urology conference showcases advancements in prostate cancer diagnostics